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group were $665.34/year per patient vs. haloperidol,
$95.05 vs risperidone, and $651.08 vs. olanzapine. In the
>65 group, patients persisted with quetiapine for 278
days vs. 201 for risperidone (P = 0.05), 260 vs. 68 for
haloperidol (P < 0.01), and 258 vs. 192 for olanzapine 
(P = 0.16). Cost savings were $912.46/year per patient
for quetiapine vs. haloperidol, $365.93 vs. risperidone,
and $313.66 vs. olanzapine. Annual healthcare costs
were reduced by $4.75 per day (P < 0.01) for each addi-
tional day of persistence. For bipolar patients, the median
persistencies were 225 days for quetiapine compared 
with 98 for haloperidol (P < 0.01), 154 for risperidone
(P < 0.01), and 158 for olanzapine (P < 0.01), yielding
cost savings of $722.63, $403.99 and $438.13, 
respectively.
CONCLUSIONS: Quetiapine had the highest level of
therapy persistence yielding healthcare cost savings com-
pared to other antipsychotics.
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Bipolar disorder is a severe and costly condition that
accounts for approximately $7.6 billion in direct health
care costs in the US. Atypical antipsychotics are increas-
ingly being used for the treatment of Bipolar disorder.
OBJECTIVE: We conducted a retrospective study to
determine whether there are differences in resource 
utilization and cost of care between patients with bipolar
disorder receiving risperidone, olanzapine or quetiapine.
METHODS: In June 2001, 573 persons reported being
diagnosed with bipolar disorder on a self-administered
questionnaire. We compared the utilization of inpatient
and outpatient services as well as mental health-speciﬁc
resources by patients receiving risperidone, olanzapine, or
quetiapine over the previous six months. Drug costs were
not included in the analysis. A regression model was used
to control for use of other drug classes. National cost
multipliers published by the U.S. Census Bureau, 2000,
were used to calculate the cost of care.
RESULTS: Out of the 573 respondents, 108 had sufﬁcient
information on resource utlization for analysis. When
controlling for use of other drug classes, the olanzapine
group (n = 48) had a higher utilization of outpatient 
services (p = 0.008) compared to risperidone (n = 31). The
risperidone group also had lower utilization of inpatient
and outpatient services compared to quetiapine (n = 29),
but the differences were not statistically signiﬁcant. The
cost of care for all services was $8579, $4349, and $5221
for olanzapine, risperidone, and quetiapine, respectively,
while the cost of mental health services was $6186,
$2775, and $4022, respectively.
CONCLUSION: Patients with bipolar disorder receiving
risperidone appear to have lower utilization of healthcare
services and lower costs of care.
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OBJECTIVES: To derive utility values associated with
differing symptoms states of schizophrenia using time
trade-off (TTO) methodology in a community sample.
METHODS: Four clinically signiﬁcant symptom states
were derived from clinical trial data. Scenarios were
grouped into non-responders with extrapyramidal symp-
toms (EPS), non-responders without EPS, responders with
EPS and responders without EPS. A sample of the general
population were given a presentation on the symptoms of
schizophrenia and the side effects of treatment. Respon-
dents then completed the TTO questionnaire in small
groups, trading from a base of 30 years.
RESULTS: 70 participants completed the questionnaire
and traded in a “rational” manner. A mean score of 85%
in a 10-question quiz regarding symptoms of schizophre-
nia and EPS indicated that the presentation had been
understood by participants. The utility scores for each
group were as follows: non-responders with EPS 0.63
(11.0 years traded); non-responders without EPS 0.72
(8.3 years); responders with EPS 0.79 (6.3 years) and
responders without EPS 0.87 (3.8 years). A GEE model
used to analyse these data demonstrated a statistically sig-
niﬁcant effect of health state on mean years traded. Par-
ticipants traded signiﬁcantly more years for the responder
than the non-responder state and, irrespective of respon-
der categorisation, traded signiﬁcantly more years for the
“no EPS” state.
CONCLUSIONS: These results show the ability of a
community sample to value symptoms of schizophrenia
and the side effects of treatment using a time trade-off
methodology. They indicate the value of effective antipsy-
chotic medication that is also associated with a superior
EPS side-effect proﬁle. The implications of these data
when considering cost-effectiveness of antipsychotic 
medication will be discussed.
